Request availability and a quotation for your required quantity and destination.
| Product | Minoxidil 5% + Finasteride 0.1% - Morr F 5 Solution |
|---|---|
| Categories | Hair Care |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Product category: Hair Care
Product: Morr F 5 Solution
Presentation: Topical scalp solution
Regulatory note: Verify local labeling and supply requirements.
This topical scalp solution is listed as 5% minoxidil with 0.1% finasteride. Minoxidil 5% topical solutions have evidence supporting use in certain patterns of hereditary hair loss; the exact product directions and approved population depend on its label. Topical finasteride combinations are not FDA-approved in the United States, and systemic finasteride exposure is possible.
Minoxidil encourages hair growth in some people with hereditary scalp hair loss. Product strength, formulation, duration and proper diagnosis matter; higher concentrations or combination drugs require more careful medical oversight.
Follow the verified pack-specific directions. Apply only to the intended scalp area; avoid eyes and broken skin. Wash hands after application and avoid exposing others to wet solution. Do not increase concentration or frequency independently.
Scalp irritation and unwanted hair growth are possible. Stop and seek medical attention for chest pain, faintness, severe dizziness, rapid heartbeat or swelling. Finasteride can be absorbed through the skin; the FDA has reported systemic adverse effects with compounded topical finasteride and warns about transfer exposure, especially during pregnancy.
Tugain 5 · Morr F 5 · Finalo 1 mg. Product comparisons do not imply equal indications or suitability.
U.S. FDA alert: topical finasteride risks
Topical minoxidil is commonly used for selected patterns of androgenetic alopecia; confirm the exact product’s indication with a clinician.
Initial improvement can take several months; individual response varies.
Some people notice temporary increased shedding early in treatment. Persistent or unusual shedding merits assessment.
Higher concentration does not establish better outcomes and may increase adverse effects; 10% is not the usual U.S.-approved topical strength.
Scalp irritation and unwanted hair can occur; absorbed finasteride may also cause systemic sexual, mood or other adverse effects.
Eligibility depends on the exact formulation and clinician guidance; finasteride exposure is particularly concerning in pregnancy.
Rinse thoroughly with cool running water and seek medical advice if irritation persists.
Do not apply to irritated, injured or infected scalp without clinical assessment.
Any maintained regrowth may be lost after treatment stops.
Do not combine systemic and topical medicines without medical supervision because adverse effects and exposure may increase.
Related hair-loss guide: minoxidil versus finasteride for pattern hair loss. Treatment selection and safety depend on diagnosis and the exact formulation.
Cureiva handles lawful product enquiries subject to product verification, destination-country requirements and any applicable prescriptions. Source-supported educational content; independent clinician sign-off has not been completed. Updated October 2026.